AAT 009

Drug Profile

AAT 009

Alternative Names: AAT-009; RQ-00000009; RQ-9

Latest Information Update: 28 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer RaQualia Pharma
  • Class Antidementias; Small molecules
  • Mechanism of Action Acetylcholine stimulants; Amyloid beta-protein inhibitors; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 15 Mar 2016 Phase I development is ongoing in Japan
  • 14 Apr 2009 RQ 00000009 is available for licensing (http://www.raqualia.com)
  • 08 Apr 2009 Phase-I clinical trials in Alzheimer's disease in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top